Authors
Latest:
Gargi Basu on Alterations in the Cell Cycle Checkpoint Pathway in Breast CancerGargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.
Latest:
Dr. Steinberg on the Standard of Care in Non-Muscle Invasive Bladder CancerGary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).
Latest:
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment LandscapeClosing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Latest:
Dr. Kirsh on Advancements in Diagnosing Prostate CancerGary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.
Latest:
Dr. Danuser Discusses Impact of RacP29S Mutation in MelanomaGaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Khan on Implications of the REFLECT Trial in HCCGazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses the implications of the REFLECT trial in advanced hepatocellular carcinoma (HCC).
Latest:
Dr. Bratslavsky on the Evaluation and Management of Kidney CancerGennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.
Latest:
Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer CenterThe Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.
Latest:
Dr. Krampitz on Therapeutic Targets in pNETsGeoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.
Latest:
Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast CancerGeoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.
Latest:
Dr. Oxnard Discusses RET Fusions in NSCLCGeoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer Institute, discusses RET fusions in non–small cell lung cancer.
Latest:
Dr. Sklar on Challenges With Clinical Trials in Bladder CancerGeoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.
Latest:
Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in MelanomaGeoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Latest:
Dr. Uy on Therapy Selection in Acute Myeloid LeukemiaGeoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).
Latest:
Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal AdenocarcinomaGeoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.
Latest:
Evolving Treatment Options for Older Patients with AMLAbout 13,300 new cases of acute myeloid leukemia (AML) are diagnosed yearly, and nearly 9,000 deaths occur in the United States.
Latest:
Dr. Demetri on Larotrectinib in TRK-Fusion GI CancersGeorge D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.
Latest:
Dr. Demetri Discusses Regorafenib for GIST PatientsDr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.
